HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

In vivo efficacy of HAT therapy against transplantable murine myelomas resistant to purine analogs.

Abstract
The therapeutic efficacy of antineoplastic purine analogs can be jeopardized by the emergence of drug-resistant mutant subpopulations of tumor cells. To determine whether such mutant populations might be eradicable in vivo with the type of HAT combination (hypoxanthine + an antifolate + thymidine) known to be selectively cytotoxic to them in vitro, 2 thioguanine-resistant BALB/c murine myeloma lines were transplanted into BALB/c mice to produce tumors capable of progressive growth in the absence of therapy. Treatment of these mice with a modified HAT regimen induced permanent tumor regressions in 37/44 mice; the same treatment was ineffective against tumors produced by a non-mutant myeloma line from which one of the mutant sublines had been derived.
AuthorsF L Moolten
JournalCancer letters (Cancer Lett) Vol. 31 Issue 3 Pg. 305-9 (Jun 1986) ISSN: 0304-3835 [Print] Ireland
PMID3719570 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Hypoxanthines
  • Hypoxanthine
  • Thioguanine
  • Aminopterin
  • Thymidine
Topics
  • Aminopterin (administration & dosage, therapeutic use)
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Drug Resistance
  • Hypoxanthine
  • Hypoxanthines (administration & dosage, therapeutic use)
  • Mice
  • Mice, Inbred BALB C
  • Mutation
  • Plasmacytoma (drug therapy)
  • Thioguanine (therapeutic use)
  • Thymidine (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: